Through a partnership with Velico Inc., a Massachusetts-based medical supply company, South Texas Blood & Tissue will be taking part in a groundbreaking blood preservation technology that could help save even more lives.
Building on its 50-year history of saving and enhancing lives through the healing power of human cells and tissue, BioBridge Global announced today that it is consolidating its end-to-end Cell and Gene Therapy Services portfolio into a new, highly integrated and coordinated operating subsidiary, BBG Advanced Therapies.
BioBridge Global’s R&D Analytical Development team now has a specialized lab to call their own.
As BioBridge Global celebrates its 50th anniversary, the nonprofit and its subsidiaries are evolving to help build the future of healthcare.
BioBridge Global CEO Martin Landon spoke on a panel during the Invest San Antonio 2023-2024 Conference on Thursday, noting the organization’s growing capabilities.
South Texas Blood & Tissue leaders were featured in a webinar on an innovative program to collect whole blood-derived platelets. Audra Taylor (VP, Blood Operations)
BioBridge Global celebrated another major advanced therapies milestone March 1, opening its first stand-alone Cell Therapy Testing Laboratory.
The University of Texas at San Antonio and GenCure, a subsidiary of the San Antonio nonprofit BioBridge Global, have signed a master services agreement to collaborate on the development of cellular therapy products, services, and testing.
BioBridge Global is proud to announce that 12 abstract submissions were accepted to present as research posters during the AABB 2023 Annual Meeting taking place Oct. 14-17 in Nashville, TN.
A collation of Texas cities, including San Antonio, has landed one of three national hubs from the new federal Advanced Research Projects Agency for Health, an agency expected to send billions on healthcare research in the coming years.
BioBridge Global CEO Marty Landon recently sat down with editors from Invest: San Antonio magazine for a Q and A on how the organization is meeting the demand for local healthcare and the growing advanced therapies market in today’s economic climate.
MasterControl has published a case study of its experience with BioBridge Global to demonstrate the effectiveness and abilities of its quality control and manufacturing solutions software in the advanced therapies industry.